

Supplementary Table 4. Odds ratios for the hepatic steatosis stages according to u-NCR in insulin users ($n=300$)

Model	Hepatic steatosis stage 1 (S1)		Hepatic steatosis stage 2 (S2)		Hepatic steatosis stage 3 (S3)	
	aOR (95% CI)	<i>P</i> value	aOR (95% CI)	<i>P</i> value	aOR (95% CI)	<i>P</i> value
1	1.26 (0.70–2.24)	0.441	0.74 (0.43–1.25)	0.260	0.78 (0.46–1.33)	0.362
2	1.39 (0.76–2.52)	0.282	0.77 (0.44–1.36)	0.372	0.83 (0.48–1.43)	0.503
3	1.46 (0.76–2.79)	0.263	0.86 (0.48–1.54)	0.613	0.77 (0.43–1.38)	0.372
4	1.84 (0.90–3.74)	0.093	0.56 (0.28–1.13)	0.110	0.57 (0.29–1.14)	0.110

Model 1 was adjusted for age, male sex, body mass index, and duration of diabetes; Model 2 adjusted for Model 1 parameters plus hypertension, lipid medication; Model 3 adjusted for Model 2 parameters plus triglyceride, alanine aminotransferase; Model 4 adjusted for Model 3 parameters plus glycosylated hemoglobin, insulin.

u-NCR, urinary *N*-acetyl- β -D-glucosaminidase to creatinine ratio; aOR, adjusted odds ratio; CI, confidence interval.